Alivus Life Sciences Ltd
NSE: ALIVUS · Pharmaceuticals · sector
₹1,262.00NSE close 2026-10-26
Key numbers
Market cap₹15,490 cr
Price₹1,262.00
52w high / low₹1,494 / ₹819
P/E25.7xSector median 27.9x
P/B4.6xSector median 2.9x
Book value₹271.5
Dividend yield0.39%Sector median 0.48%
ROE19.6%Sector median 11.7%
ROCE24.2%Sector median 12.3%
OPM31.3%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA18.1xSector median 18.6x
Interest cover148.5x
Current ratio5.21x
Sales growth 3y+5.7%Sector median +9.6%
Profit growth 3y+6.5%Sector median +13.3%
PEG3.98x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹783 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 148.5x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 3 of the last 5 years (FY25, FY24, FY23).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 12% of net profit in the last 12 months.
- Debtor days went from 122 (FY24) to 153 (FY26).
- Dividend paid in 4 of the last 5 financial years.
- Price ₹1,262.00 on 2026-10-26: -15.5% from the 52-week high, +54.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,417.90 · low ₹861.50
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| EBITDA | 134 | 190 | 198 | 172 | 179 | 206 | 215 | 212 |
| OPM % | 26.5% | 29.7% | 30.5% | 28.6% | 30.5% | 30.6% | 31.1% | 33.1% |
| Other income | 9 | 10 | 10 | 9 | 15 | 14 | 23 | 22 |
| Net profit | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS (₹) | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 |
| Revenue YoY | +16.0% | +4.8% | +6.1% | +6.4% | ||||
| Profit YoY | +36.4% | +9.7% | +14.7% | +31.7% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| EBITDA | 616 | 642 | 674 | 683 | 772 | 811 |
| Net profit | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS (₹) | 35.63 | 38.11 | 38.43 | 39.63 | 45.99 | 49.12 |
| Revenue growth | +1.8% | +5.6% | +4.5% | +6.9% | +7.9% | |
| Profit growth | +11.5% | +0.8% | +3.1% | +16.2% | +21.7% | |
| Dividend / share (₹) | 10.50 | 31.50 | 22.50 | – | 5.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +5.7% | – | +7.9% |
| Net profit | +6.5% | – | +21.7% |
| EPS | +6.5% | – | – |
| Share price | – | – (2y) | +36.1% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 2,138 | 2,332 | 2,817 | 3,332 |
| Borrowings | – | 0 | 0 | 0 | 0 |
| Cash & equivalents | – | 309 | 302 | 549 | 783 |
| Total assets | – | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed assets | – | 775 | 795 | 943 | 1,018 |
| Capital work in progress | – | 49 | 101 | 94 | 273 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 807 | 765 | 970 | 1,073 |
| Inventory | – | 604 | 667 | 674 | 692 |
| Payables | – | 397 | 369 | 390 | 372 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 598 | 313 | 414 | 392 | 565 |
| Cash from investing | -122 | -154 | -116 | -616 | -570 |
| Cash from financing | -79 | -388 | -279 | -6 | -64 |
| Capex | 132 | 170 | 129 | 166 | 307 |
| Free cash flow | 465 | 143 | 285 | 225 | 258 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 21.8% | 20.2% | 17.2% | 16.9% |
| ROCE % | – | 29.4% | 27.1% | 23.3% | 22.7% |
| Debtor days | – | 136 | 122 | 148 | 153 |
| Inventory days | – | 217 | 243 | 228 | 237 |
| Payable days | – | 143 | 134 | 132 | 127 |
| Cash conversion cycle (days) | – | 210 | 231 | 244 | 263 |
| Working capital days | – | 227 | 236 | 285 | 306 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 74.85% |
| FIIs | 5.93% |
| DIIs | 7.03% |
| of which Mutual funds | 5.29% |
| of which Insurance | 0.24% |
| Government | 0.00% |
| Public (non-institutions) | 12.19% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% | 74.85% |
| Promoter group | % |
|---|---|
| Nirma Limited | 74.85% |
| Karnavati Holdings Inc., USA | 0.00% |
| Searles Valley Minerals Inc., USA | 0.00% |
| Searles Valley Minerals Europe, France | 0.00% |
| Searles Domestic Water Company LLC, USA | 0.00% |
| Trona Railway Company LLC, USA | 0.00% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Small Cap Fund | 2.85% |
| Government Pension Fund Global | 2.33% |
| Massachusetts Institute of Technology | 1.23% |
| Old Bridge Focused Fund | 1.07% |
1,22,777 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ALIVUS | ₹15,490 cr | 25.7x | 4.6x | 19.6% | 24.2% | 31.3% | +5.7% | 0.39% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-01 | Dividend | Dividend - Rs 5 Per Share |
| 2025-09-01 | Dividend | Dividend - Rs 5 Per Share |
| 2023-10-17 | Dividend | Interim Dividend - Rs 22.50 Per Share |
| 2023-09-22 | Other | Annual General Meeting |
| 2023-03-24 | Dividend | Interim Dividend - Rs 21 Per Share |
| 2022-09-15 | Dividend | Dividend - Rs 10.5 Per Share |
| 2021-11-22 | Dividend | Interim Dividend - Rs 10.50 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Chemical and chemical products, pharmaceuticals, medicinal, chemical and botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ALIVUS |
| BSE code | 543322 |
| ISIN | INE03Q201024 |
| Face value | ₹2.0 |
| Incorporated | 2011-06-23 |
| Website | www.alivus.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.